A short statement from CMS said the agency will consider ways to make Medicare price negotiations, begun under Biden, more ...

Julie Kim, currently Takeda’s U.S. head, will replace Weber in June 2026 and become one of the few female CEOs of a top drugmaker.

The FDA clearance aids AstraZeneca and Daiichi Sankyo’s plan to position ADCs like Enhertu ahead of chemotherapy in a variety ...

At a Senate hearing, Kennedy also said the president has directed him to examine the well-established safety of mifepristone, ...

Senators challenged Kennedy, who was nominated as health secretary by President Trump, on his long track record of ...

BioAge scrapped the drug at the center of its $198 million initial public offering last year. Elsewhere, Akero and 89bio raised $600 million combined and Allakos laid off staff.

States and providers regained access to a key healthcare payments portal late Tuesday amid pushback over the Trump ...

The expansion is a natural progression for Upperton who already develops and manufactures small molecule and biological, ...

Helicore, which is developing a GIP-blocking antibody, is the fourth obesity drug developer to receive funding from Versant ...

The approval adds a new indication for GLP-1 drugs and gives Novo an advantage over Lilly’s rival diabetes drug Mounjaro, ...

The startup says its specially constructed RNAi therapies can get deep into brain tissue, yielding new ways to treat ...

Federal agencies must stop disbursing financial assistance under a new budget directive, threatening funding for providers ...